Elicera Therapeutics AB (8E8) Price & Analysis

0 Followers

8E8 Stock Chart & Stats

€0.47

€0.03(20.86%)

At close: Jan 08 4:00 PM EST

€0.47

€0.03(20.86%)

Day’s Range― - ―

52-Week Range€0.19 - €0.67

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€15.89M

Enterprise Value€123.71M

Total Cash (Recent Filing)€17.86M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.56

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.29

Shares Outstanding66,736,374

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)10.19

Price to Sales (P/S)0.00

P/FCF Ratio-11.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.04

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetHaving no reported debt reduces refinancing and interest-rate risk and preserves strategic optionality for a clinical-stage biotech. Over the next 2–6 months, this strengthens the company’s ability to prioritize R&D and licensing deals without near-term interest obligations, lowering bankruptcy tail risk versus leveraged peers.

High Gross Margin Profile When Revenue ExistsHigh gross margins indicate the company’s underlying product or service economics can be favorable once revenue scales. For a therapy developer, strong gross margins support meaningful operating leverage as sales grow, enabling more efficient use of R&D spend and improving path to sustainable profitability if clinical programs commercialize.

Focused Immuno-oncology PipelineA clear strategic focus on next-generation CAR T and cell persistence addresses a durable, growing oncology market. This specialization supports competitive moats via platform know-how and potential partnerships, improving long-term licensing and collaboration prospects as demand for advanced cell therapies expands.

Bears Say

High Operating Cash BurnSustained negative operating and free cash flow at this scale creates short- to medium-term funding needs. Over 2–6 months this elevates dilution and financing risk, forcing the company to seek equity or partnerships that can dilute shareholders or impose milestones and governance constraints on R&D programs.

Modest And Sharply Declining RevenueVery low and rapidly declining revenue signals limited commercial traction or one-off receipts. This weakens the company’s ability to self-fund development and increases dependence on external capital or partnerships, impairing strategic flexibility and raising execution risk for clinical programs.

Large Persistent Losses And Negative ROEMassive negative margins and sharply negative ROE reflect ongoing heavy R&D spending without revenue to offset costs. Persisting losses erode equity and heighten dilution risk from future financings, making it harder to attract long-term investors and partners unless clinical milestones materially de-risk programs.

8E8 FAQ

What was Elicera Therapeutics AB’s price range in the past 12 months?

Elicera Therapeutics AB lowest stock price was €0.19 and its highest was €0.67 in the past 12 months.

What is Elicera Therapeutics AB’s market cap?

Elicera Therapeutics AB’s market cap is €15.89M.

When is Elicera Therapeutics AB’s upcoming earnings report date?

Elicera Therapeutics AB’s upcoming earnings report date is Aug 21, 2026 which is in 30 days.

How were Elicera Therapeutics AB’s earnings last quarter?

Elicera Therapeutics AB released its earnings results on Apr 21, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.009.

Is Elicera Therapeutics AB overvalued?

According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Elicera Therapeutics AB pay dividends?

Elicera Therapeutics AB does not currently pay dividends.

What is Elicera Therapeutics AB’s EPS estimate?

Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Elicera Therapeutics AB have?

Elicera Therapeutics AB has 66,736,374 shares outstanding.

What happened to Elicera Therapeutics AB’s price movement after its last earnings report?

Elicera Therapeutics AB reported an EPS of -€0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.677%.

Which hedge fund is a major shareholder of Elicera Therapeutics AB?

Currently, no hedge funds are holding shares in DE:8E8

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several drug candidates, including ELC-100, which is currently undergoing Phase I/II trials for neuroendocrine tumors. The company is also advancing ELC-201 and ELC-401 through preclinical development, with ELC-401 specifically targeting glioblastoma multiforme (a form of brain tumor). Furthermore, Elicera is developing ELC-301, a CAR T-cell therapy intended for the treatment of Non-Hodgkin's B-cell lymphoma. A cornerstone of their work is the iTANK technology platform, engineered to enhance the efficacy of their CAR T-cell therapies and stimulate killer T-cells to attack cancerous cells.